Holdings (36)
Name | Sector | Instrument | Assets |
---|---|---|---|
Sun Pharmaceutical Industries Ltd. | Healthcare | Equity | 12.57% |
Divi's Laboratories Ltd. | Healthcare | Equity | 9.49% |
Lupin Ltd. | Healthcare | Equity | 5.82% |
Cipla Ltd. | Healthcare | Equity | 5.62% |
Dr. Reddy's Laboratories Ltd. | Healthcare | Equity | 5.49% |
Apollo Hospitals Enterprise Ltd. | Healthcare | Equity | 5.34% |
Medplus Health Services Ltd. | Healthcare | Equity | 4.2% |
Glaxosmithkline Pharmaceuticals Ltd. | Healthcare | Equity | 3.73% |
Vijaya Diagnostic Centre Ltd. | Healthcare | Equity | 3.24% |
Narayana Hrudayalaya Ltd. | Healthcare | Equity | 2.94% |
Returns and rankings
1Y | 3Y | 5Y | All | |
---|---|---|---|---|
Fund Returns | 14.76% | 26.62% | 23.11% | 17.73% |
Category Average | 15.80% | 24.69% | 21.83% | NA% |
Rank Within Category | 11.00% | 4.00% | 5.00% | NA% |
Expense ratio, exit load and tax
Expense ratio: 0.89%
Inclusive of GST
Exit load
Exit load of 1% if redeemed within 1 month.
Stamp duty
0.005% (from July 1st, 2020)
Tax implication
Returns are taxed at 20%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 12.5% on returns of Rs 1.25 lakh+ in a financial year.
Fund management
Education
Mr. Bhan is an MBA (Finance) and CFA.
Experience
Prior to joining Nippon India Mutual Fund, he has worked with Emkay Share & Stock Broker Pvt. Ltd, Shah & Sequeira Invst. Pvt. Ltd, ICFAI- Securities Research Center Analyst - Equity Research.
Managed Schemes
Nippon India Large Cap Fund Direct Growth
Nippon India Multi Cap Fund Direct Growth
Nippon India Pharma Fund Direct Growth
Reliance Close Ended Equity Fund Series A Direct Growth
Reliance Close Ended Equity Fund Series B Direct Growth
Reliance Close Ended Equity Fund II Series A Direct Growth
Nippon India India Opportunities Fund Series A Direct Growth